U.S. markets closed

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
29.75+0.53 (+1.81%)
At close: 4:00PM EST

29.75 0.00 (0.00%)
After hours: 4:16PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Outside Bar (Bearish)

Outside Bar (Bearish)

Previous Close29.22
Open29.60
Bid27.51 x 1000
Ask29.99 x 800
Day's Range28.83 - 29.85
52 Week Range13.12 - 29.85
Volume568,819
Avg. Volume621,351
Market Cap1.567B
Beta (5Y Monthly)1.38
PE Ratio (TTM)12.34
EPS (TTM)2.41
Earnings DateFeb 23, 2021 - Mar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
50% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Exact Sciences Scores Relative Strength Rating Upgrade; Hits Key Threshold
    Investor's Business Daily

    Exact Sciences Scores Relative Strength Rating Upgrade; Hits Key Threshold

    Exact Sciences saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 75 to 85. As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength. Exact Sciences is now considered extended and out of buy range after clearing a 139.36 buy point in a second-stage cup with handle.

  • Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference
    GlobeNewswire

    Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference

    ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021, at 9:10 a.m. ET, and will be available for virtual investor meetings. A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of this webcast will be available for 60 days on the Company's website after the conference.About Supernus Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations (“on-off” episodes) in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.See full Prescribing Information for our products here: Trokendi XR, Oxtellar XR, APOKYN, MYOBLOC, and XADAGO.All trademarks are the property of their respective owners.CONTACTS: Jack A. Khattar, President and CEO Jim Kelly, EVP & Chief Financial Officer Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591orINVESTOR CONTACT: Peter Vozzo Westwicke, an ICR Company Office: (443) 213-0505 Mobile: (443) 377-4767 Email: peter.vozzo@westwicke.com

  • Company News for Dec 24, 2020
    Zacks

    Company News for Dec 24, 2020

    Companies in the news are: SUPN, PLTR, JAGX, SRNE